Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.40 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28689779 | 0.80 | DRD2 (0.42) | DRD2DRD3HTR2A | |
| SCHEMBL1240475 | 0.75 | FGFR1 (0.41) | FGFR1FGFR2FGFR4FGFR3HTR2A | |
| SCHEMBL28442589 | 0.73 | DRD2 (0.43) | DRD2DRD3HTR2AKCNH2TAAR1 | |
| SCHEMBL1243099 | 0.72 | FGFR1 (0.44) | FGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL28461089 | 0.72 | DRD2 (0.37) | DRD2DRD3 | |
| SCHEMBL28455710 | 0.72 | — | — | |
| SCHEMBL27904261 | 0.71 | DRD2 (0.54) | DRD2DRD3 | |
| SCHEMBL27551469 | 0.71 | DRD2 (0.46) | DRD2DRD3HTR2AKCNH2TAAR1 | |
| SCHEMBL27904263 | 0.70 | DRD2 (0.43) | DRD2DRD3HTR2A | |
| SCHEMBL28461162 | 0.70 | MAPT (0.36) | DRD2DRD3HTR2AKCNH2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10472315-B2 | Inhibitors of methionine aminopeptidases and methods of treating disorders | THE JOHNS HOPKINS UNIVERSITY (US) | 2019-11-12 | — | — | US | disclosed |
| US-20120196852-A1 | INHIBITORS OF METHIONINE AMINOPEPTIDASES AND METHODS OF TREATING DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-08-02 | — | — | US | disclosed |
| WO-2011017519-A2 | INHIBITORS OF METHIONINE AMINOPEPTIDASES AND METHODS OF TREATING DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196852-A1 | INHIBITORS OF METHIONINE AMINOPEPTIDASES AND METHODS OF TREATING DISORDERS | METAP1, METAP2, ENPEP | DRD2 2682/4885DRD3 2979/4885FGFR1 4719/4885 |
| US-10472315-B2 | Inhibitors of methionine aminopeptidases and methods of treating disorders | METAP1, METAP2, ENPEP | DRD2 2682/4885DRD3 2979/4885FGFR1 4719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.